These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6768149)

  • 1. In vitro thrombogenicity tests of factor IX concentrates. I. A survey of available assays.
    Prowse CV; Chirnside A; Elton RA
    Thromb Haemost; 1980 Feb; 42(5):1355-67. PubMed ID: 6768149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
    Prowse CV; Boffa MC; Guthrie C; Pepper DS
    Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated clotting factors in factor IX concentrates.
    Hultin MB
    Blood; 1979 Nov; 54(5):1028-38. PubMed ID: 497395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV; Williams AE
    Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
    Lundblad RL; Kingdon HS; Mann KG; White GC
    Thromb Haemost; 2000 Dec; 84(6):942-8. PubMed ID: 11154139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of factor VIII--bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors: thrombin generation test in the presence of collagen-activated platelets.
    Sultan Y; Loyer F
    J Lab Clin Med; 1993 Mar; 121(3):444-52. PubMed ID: 8445292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
    MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
    Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation.
    Kjalke M; Monroe DM; Hoffman M; Oliver JA; Ezban M; Roberts HR
    Thromb Haemost; 1998 Oct; 80(4):578-84. PubMed ID: 9798973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrophotometric determination of factor Xa generation in factor IX concentrates.
    Pepper DS; Banhegyi D; Howie A
    Thromb Haemost; 1977 Jun; 37(3):535-40. PubMed ID: 578033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program.
    Brandt JT; Arkin CF; Bovill EG; Rock WA; Triplett DA
    Arch Pathol Lab Med; 1990 Feb; 114(2):135-41. PubMed ID: 2405809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor assay (VIII and IX) results in the College of American Pathologists Survey Program (1980-1982).
    Christensen RL; Triplett DA
    Am J Clin Pathol; 1983 Oct; 80(4 Suppl):633-42. PubMed ID: 6414289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of factor XI in a dilute thromboplastin assay of extrinsic coagulation pathway.
    He R; Xiong S; He X; Liu F; Han J; Li J; He S
    Thromb Haemost; 2001 Jun; 85(6):1055-9. PubMed ID: 11434684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin generation assay using factor XIa to measure factors VIII and IX and their glycoPEGylated derivatives is robust and sensitive.
    Waters EK; Hilden I; Sørensen BB; Ezban M; Holm PK
    J Thromb Haemost; 2015 Nov; 13(11):2041-52. PubMed ID: 26340413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing for potential thrombogenicity of prothrombin complex concentrates.
    Snape TJ
    Dev Biol Stand; 1979; 44():199-204. PubMed ID: 544295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding to phospholipid protects factor VIII from inactivation by human antibodies.
    Barrowcliffe TW; Kemball-Cook G; Gray E
    J Lab Clin Med; 1983 Jan; 101(1):34-43. PubMed ID: 6401316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitors.
    Ruinemans-Koerts J; Peterse-Stienissen I; Verbruggen B
    Thromb Haemost; 2010 Nov; 104(5):1080-2. PubMed ID: 20806127
    [No Abstract]   [Full Text] [Related]  

  • 17. [Thrombin formation in factor IX concentrates and FEIBA (factor eight inhibitor bypassing activity) (proceedings)].
    Hofmann V; Ermanni M; Straub PW
    Schweiz Med Wochenschr; 1978 Oct; 108(41):1600. PubMed ID: 694497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of coagulation factors on intrinsic thrombin generation.
    Stief TW; Otto S; Renz H
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):67-71. PubMed ID: 17179830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Standardization of the thromboplastin generation test for the determination of antihemophilic globulin A (VIII) and B (IX)].
    Bergmann A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 93(3):376-80. PubMed ID: 4195285
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations.
    Kempton CL; Hoffman M; Roberts HR; Monroe DM
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):861-6. PubMed ID: 15653564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.